Form 8-K - Current report:
SEC Accession No. 0001213900-24-092248
Filing Date
2024-10-30
Accepted
2024-10-30 16:15:08
Documents
16
Period of Report
2024-10-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0219204-8k_aditxt.htm   iXBRL 8-K 47954
2 FORM OF SECURITIES PURCHASE AGREEMENT (OCT 28, 2024) ea021920401ex10-1_aditxt.htm EX-10.1 267027
3 FORM OF REGISTRATION RIGHTS AGREEMENT (OCT 28, 2024) ea021920401ex10-2_aditxt.htm EX-10.2 190861
4 TRANSCRIPT OF STAKEHOLDER UPDATE- OCTOBER 28, 2024 ea021920401ex99-1_aditxt.htm EX-99.1 105527
  Complete submission text file 0001213900-24-092248.txt   926651

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adtx-20241028.xsd EX-101.SCH 3009
6 XBRL LABEL FILE adtx-20241028_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE adtx-20241028_pre.xml EX-101.PRE 22355
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0219204-8k_aditxt_htm.xml XML 3784
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 241410509
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)